Advertisements

Berlipril H

Quick links to important sections

Berlipril H

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Berlipril H

Quick Facts

Property Description
Active ingredient Enalapril maleate, Hydrochlorothiazide (HCTZ)
Form Fixed-dose combination tablet (Oral)
Pharmacological class Combined Antihypertensive Drug (ACE Inhibitor with Thiazide Diuretic)
Common use Management of high blood pressure (Hypertension)
Origin Synthetic

1. Berlipril H: Identity and Classification

Berlipril H is a synthetic, prescription-only pharmaceutical product administered orally as a fixed-dose combination tablet. It is categorized as a Combined Antihypertensive Drug, specifically belonging to the class of ACE Inhibitors with Thiazides. This fixed-dose combination (FDC) approach is a distinguishing feature, signifying that it provides the dual benefits of a vessel relaxant and a fluid-reducing agent in a single pill, which is clinically recognized for improving patient adherence compared to taking two separate tablets.

The purpose of combining these two components is to provide a comprehensive dual approach for the management of high blood pressure, known as hypertension. This combination is a therapeutic strategy for reducing cardiovascular risk associated with elevated pressure. Therefore, the medicine is used to support sustained control over pressure levels in adults.

2. Composition and General Therapeutic Purpose

The tablet’s composition includes the active ingredients Enalapril maleate and Hydrochlorothiazide, along with necessary excipients to form the solid oral dosage form. Enalapril is notable for being a prodrug, meaning it is converted into its therapeutically active metabolite, enalaprilat, after ingestion. This conversion mechanism is a specific property of the enalapril substance.

The general therapeutic purpose of this fixed-dose combination is to help maintain controlled blood pressure levels, which is crucial for reducing the long-term risk of cardiovascular complications, including stroke and heart failure. Both Enalapril and Hydrochlorothiazide are included on the Model List of Essential Medicines due to their roles in managing pressure and supporting the circulatory system.

Regulatory References

  1. Enalapril and Hydrochlorothiazide: MedlinePlus Drug Information
  2. Model List of Essential Medicines - Antihypertensive medicines
Advertisements

What side effects are possible with Berlipril H?

Possible Side Effects and Safety Information

The safety profile of Berlipril H (Enalapril maleate and Hydrochlorothiazide) is characterized by adverse reactions documented in official regulatory documents, which group possible effects by frequency and the body system affected.

Official Adverse Reactions and Frequency

Side effects are officially classified according to their rate of occurrence based on regulatory criteria:

  • Very Common (Affects 1 in 10 people or more): Dizziness and asthenia (weakness or lack of energy) are frequently reported, particularly following the initial doses.
  • Common (Affects up to 1 in 10 people): Headache, fatigue, dry or persistent cough, nausea, and low blood pressure (hypotension) are common. Metabolic changes such as shifts in blood potassium and uric acid levels are also listed as common effects.
  • Uncommon/Rare: Less frequent effects include palpitations, vomiting, and skin rash. Rare, but clinically significant, reactions include pancreatitis, severe blood disorders (like agranulocytosis), and liver problems (like hepatic failure or jaundice).

System-Organ-Class Involvement

Adverse effects are documented across several body systems:

System-Organ Class Example Adverse Reaction
Vascular Disorders Hypotension, including orthostatic effects
Respiratory Disorders Cough (a class effect of ACE inhibitors)
Metabolism Disorders Electrolyte imbalances (low potassium or high potassium)
Nervous System Headache, Dizziness, Syncope (fainting)

Serious Safety Considerations

The regulatory label explicitly identifies rare but serious adverse reactions, including Angioedema (swelling of the face, tongue, or throat) and acute renal failure. The risk of hypotension and dizziness is noted to be more frequent after the initial dose or upon dose increase.

Population-Specific Constraints

Official safety documentation outlines specific constraints for certain populations. The medicine is contraindicated during the second and third trimesters of pregnancy. It is not recommended for individuals with a history of Angioedema related to prior ACE inhibitor use or those with severe renal impairment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is derived exclusively from official government regulatory documents detailing the documented manifestations and required emergency actions for an overdose of Berlipril H (Enalapril maleate and Hydrochlorothiazide).


Documented Overdose Presentations

Element Official Regulatory Documentation
Documented Manifestations Marked hypotension (severely low blood pressure), bradycardia or tachycardia, dizziness, and severe electrolyte imbalances (e.g., hypokalemia, hyponatremia).
Serious Outcomes Potential for circulatory shock, acute renal failure (oliguria or anuria), and cardiac rhythm abnormalities due to electrolyte shifts.

Required Emergency Actions

Official regulatory guidance mandates that any suspected overdose requires the user to seek immediate medical attention.

Immediate help-seeking is required if the person exhibits signs of severe systemic instability, such as fainting, inability to be awakened (stupor), or signs of circulatory shock.


Management and Monitoring

Treatment is officially defined as symptomatic and supportive. Regulatory labels note that no specific antidote is known for this overdose. Procedural steps described often include the intravenous infusion of normal saline to correct volume depletion and the active correction of fluid and electrolyte imbalances. Intensive monitoring of blood pressure, serum electrolytes, and renal function is required due to the risk of life-threatening complications. In the elderly, severe hypotension and poor organ perfusion are specifically noted as overdose risks.

Advertisements

Therapeutic Uses of Berlipril H

What Berlipril H Treats: Main Uses and Benefits

The combination of Enalapril and Hydrochlorothiazide is a long-term treatment specifically applied within the therapeutic domain of hypertensiology. Its primary use is focused strictly on managing conditions involving established, chronically elevated blood pressure. This type of combination helps lower the sustained force exerted on the blood vessels, which is an important part of managing long-term health.


Management for Uncontrolled Essential Hypertension

This medication is generally applied in adult patients diagnosed with essential hypertension (high blood pressure) whose condition requires additional management. It is used to address symptom clusters related to sustained high vascular pressure that requires supportive relief. The key therapeutic benefit is achieving consistent management of blood pressure levels, which helps with conditions where functional stability becomes affected by chronic pressure.

Supporting Long-Term Cardiovascular Stability

The medication is commonly used to help manage the long-term systemic risk associated with persistent high pressure. It supports patients with conditions involving systemic imbalance, playing a role in helping to maintain the health of vital organs like the heart, brain, and kidneys.


Quick Fact: Management of Elevated Pressure

Property Description
Primary Indication Essential Hypertension
Severity Relevance Uncontrolled or Inadequately Managed Pressure
Patient Benefit Contributes to managing symptoms related to systemic imbalance and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

The eligibility for using Berlipril H (Enalapril maleate and Hydrochlorothiazide) is strictly defined by regulatory documents, categorizing users into allowed, restricted, and contraindicated populations.

Eligibility Scope

Classification Population Status Restrictions as per Label
Approved Use Adult Patients Approved for use in adults with essential hypertension.
Not Recommended Pediatric Patients Safety and efficacy are not established for individuals under 18 years of age.
Conditional Use Severe Organ Impairment Not recommended in severe renal impairment (CrCl le 30 mL/min). Use requires caution in cases of impaired hepatic function.

Contraindicated Populations

Use of the medicine is absolutely prohibited for specific patient groups:

  • Patients with a history of angioedema related to any previous ACE inhibitor treatment, or hereditary/idiopathic angioedema.
  • Individuals with hypersensitivity to the active ingredients or to any other sulfonamide-derived drugs.
  • Patients with anuria (inability to pass urine).
  • Pregnant women in the second and third trimesters, as immediate discontinuation is required upon pregnancy detection.
  • Patients with diabetes mellitus or moderate to severe renal impairment who are taking aliskiren.
  • Patients taking a neprilysin inhibitor (e.g., sacubitril) within a 36-hour window.

Pregnancy and Lactation Eligibility: Use is contraindicated during the second and third trimesters. The medicine is not generally recommended while breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Berlipril H (Enalapril maleate and Hydrochlorothiazide) has officially documented interaction patterns structured around pharmacodynamic and pharmacokinetic effects, as defined in government regulatory labeling.

Contraindicated Combinations

Co-administration with Neprilysin Inhibitors (e.g., Sacubitril/Valsartan) is formally contraindicated due to the documented risk of angioedema, and requires a 36-hour wash-out period when switching. The use of Aliskiren is also contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR < 60 mL/min/1.73 m²).

Exposure and Pharmacodynamic Effects

Official labeling indicates that co-administration with Lithium reduces its renal clearance, resulting in increased serum concentrations and a risk of toxicity. Potassium-sparing diuretics and potassium supplements may cause an additive increase in serum potassium (hyperkalaemia). The use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can contribute to this hyperkalaemia risk and may affect renal function, particularly in elderly or volume-depleted patients. Further, Cholestyramine and Colestipol resins impair the absorption of the hydrochlorothiazide component. Alcohol co-administration is noted for the potentiation of orthostatic hypotension.

Advertisements

Mechanism of Action

Berlipril H is a combination preparation containing Enalapril and Hydrochlorothiazide, each acting through distinct mechanistic pathways.

Enalapril is a prodrug that is hydrolyzed in vivo to its active metabolite, Enalaprilat. Enalaprilat functions as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE), a peptidyl dipeptidase. ACE catalyzes the conversion of Angiotensin I to the potent vasoconstrictor Angiotensin II. Inhibition of ACE leads to decreased plasma levels of Angiotensin II, which reduces systemic vasoconstriction and lowers the Angiotensin II-mediated stimulation of Aldosterone secretion from the adrenal cortex. This cascade decreases peripheral vascular resistance and modulates renal sodium and water reabsorption.

Hydrochlorothiazide is a thiazide diuretic that targets the sodium-chloride cotransporter (NCC) located on the apical membrane of the distal convoluted tubule cells in the kidney. By acting as an inhibitor of the NCC, Hydrochlorothiazide blocks the reabsorption of sodium and chloride ions from the tubular lumen. This molecular inhibition leads to an increase in luminal solute concentration, resulting in an osmotic shift that increases the excretion of water and electrolytes, modulating overall plasma volume. The combined actions of reduced vasoconstriction and decreased plasma volume result in systemic physiological changes.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Berlipril H

The administration of Berlipril H (Enalapril maleate/Hydrochlorothiazide) is based on established parameters to ensure its appropriate use in a long-term treatment plan. The medicine is supplied as a fixed-dose combination tablet intended solely for oral administration.

Dosing and Scheduling

The standardized regimen for adults typically involves taking one tablet once daily. While the dose is usually taken once a day, some regimens may allow administration to be divided into two daily doses. The tablet can be taken with or without food, providing flexibility in daily scheduling. However, it is procedurally important to maintain consistency by taking the dose around the same time each day.

Feature Official Use Context
Administration Route Oral (Tablet)
Standard Frequency Once Daily
Food Relationship With or without food
Contextual Status Reserved for Maintenance Therapy

Procedural Constraints

The fixed-dose combination is generally not suitable for initiating therapy in patients with essential hypertension; individual component titration is typically recommended before transitioning to the combination product. Regarding missed doses, the general procedure involves not taking a double dose to compensate. Instead, the missed dose should be skipped, and the regular schedule should be continued with the next dose.

Specific considerations exist for certain patient populations. For instance, the combination is not recommended for patients with severe renal impairment (Creatinine Clearance less than 30 mL/min). Furthermore, the safety and efficacy of the combination have not been established for pediatric use in patients under 18 years of age. The overall approach defines the medicine as part of a long-term therapy regimen for chronic conditions.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored whether the drug may be associated with changes in symptom severity.


Clinical Trial Findings

Primary Efficacy Studies

Research has explored whether the drug may be associated with changes in symptom severity. The primary study included assessment of relevant biomarkers. Specifically, the study evaluated whether the drug was associated with changes in symptom severity over a 12-week period.

  • Studies have explored different starting doses.

Combination Therapy

Studies examined whether the combination therapy was associated with changes in pain scores over time. Participants receiving the combination were observed for 6 months. Research has compared this treatment to existing options.


Patient Subgroups and Safety Profile

Research in Specific Populations

Studies have included people with various chronic conditions. Research has also explored the effects in an older adult population. The research found that results were mixed regarding the consistency of observations across all age groups studied. Based on available research, it is not yet clear whether the drug's activity varies in people with mild kidney impairment compared to those with normal function.

Safety and Tolerability Profile

The primary study included assessment of relevant biomarkers. Research documented the incidence of adverse events reported during the studies.

Key Studies & References

  1. Adverse Effects of Angiotensin-Converting Enzyme Inhibitors in Humans: A Systematic Review and Meta-Analysis of 378 Randomized Controlled Trials
  2. Enalapril: Clinical use, adverse effects, and dosage
  3. [The Berlipril and Retalzem treatment of hypertension patients: the dynamics of the clinico-hemodynamic indices and of the vasodilating humoral factors]
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Berlipril H (FAQ)


Q: What is the main difference between Berlipril H and just Berlipril?

Berlipril H is described in official product information as a fixed-dose combination medication. This means it contains two active ingredients: an ACE inhibitor (Enalapril) and a diuretic (Hydrochlorothiazide). The implied single-component drug, Berlipril, usually refers to just the ACE inhibitor, Enalapril.


Q: Is Berlipril H a type of 'water pill'?

Yes, Berlipril H contains two active components, one of which is Hydrochlorothiazide. This substance belongs to a class of medications called diuretics, which are commonly referred to as 'water pills' because they work with the kidneys to help remove excess salt and water from the body.


Q: How long does it usually take to feel a change after starting Berlipril H?

Official information indicates that some people may observe an initial improvement in blood pressure within a few hours of the first dose. However, the maximum blood pressure-lowering effects that define the medicine's full action may require several weeks to fully develop in the body.


Q: Are there any common foods or drinks to avoid while taking Berlipril H?

Official advice includes caution regarding moderately high or high potassium dietary intake and to use salt substitutes containing potassium with caution, as the medication can affect the body's potassium levels. Official warnings also note that consuming alcohol can increase the risk of side effects like dizziness and hypotension (low blood pressure).


Q: Can older people safely use Berlipril H?

Official guidance permits the use of this combination in older adults. Official information suggests that treatment for older adults may be initiated with lower doses and gradually adjusted. This cautious approach is described due to potential age-related changes in how the body processes the medication and an increased possibility of effects like low blood pressure.


Q: Is Berlipril H suitable for people with diabetes?

Individuals with diabetes can use this medication. Official information states that the diuretic component (Hydrochlorothiazide) may affect blood sugar levels. Official product information suggests that blood glucose should be monitored regularly, and any changes observed should be discussed with a healthcare provider.


Q: Do studies show that Berlipril H helps protect against heart problems?

Official documentation states the medication is used to manage high blood pressure, a practice recognized in reducing the long-term risk of major cardiovascular events like stroke. Additionally, official information on the ACE inhibitor component (Enalapril) confirms its established role in reducing the rate of heart failure development.


Q: Does Berlipril H have a generic version available?

Yes, medications containing the combination of the two active ingredients, enalapril and hydrochlorothiazide, are described in market information as being widely available in generic form.


Q: Can Berlipril H affect my sleep?

Official product information lists difficulty sleeping (insomnia) as a possible side effect of this medication. Additionally, the diuretic component may cause increased urination, which could potentially affect sleep.


Q: Is it okay to drive or operate machinery while taking Berlipril H?

Regulatory warnings advise using caution when performing tasks that require concentration, such as driving or operating machinery. This is because the medication can cause side effects like dizziness or fainting, particularly when first starting treatment or when the dose is changed.


Q: What happens if I suddenly stop taking Berlipril H?

Official warnings state that abruptly discontinuing the medication without consulting a healthcare provider is not advised, as it may lead to an uncontrolled and potentially rapid rise in blood pressure.


Q: Can this medication affect men's health or sexual function?

Official regulatory product information lists a decrease in sexual ability, drive, or performance as a possible side effect. This may include experiencing difficulty getting or maintaining an erection (erectile dysfunction).


Q: Is Berlipril H used to treat heart failure?

The fixed-dose combination (Berlipril H) is officially approved for treating hypertension (high blood pressure). However, the ACE inhibitor component (Enalapril) is separately indicated in official documents for the treatment of symptomatic congestive heart failure and related conditions.


Q: Can high salt intake interfere with Berlipril H's effectiveness?

Official guidelines suggest minimizing excessive salt intake, as it may interfere with the intended blood pressure-lowering effect of the medication. This is because high dietary salt intake is generally known to reduce the effectiveness of most antihypertensives.


Q: Are there specific symptoms that mean I should contact a healthcare professional immediately?

Official product labeling identifies several rare but serious side effects that require immediate medical attention. These include signs of Angioedema (swelling of the face, tongue, or throat) and difficulty breathing or swallowing. Other serious concerns include signs of liver problems (jaundice, dark urine) or fainting.


Q: Is there a warning about sun exposure while on Berlipril H?

Yes, official product information includes a warning that the diuretic component (Hydrochlorothiazide) may cause increased sensitivity to the sun. Official recommendations include measures to limit sun exposure and use protective clothing and sunscreen.


Q: Do I need to change my diet when taking Berlipril H?

Regulatory advice suggests being cautious with foods or substitutes that are high in potassium because the medicine can affect the body's potassium levels. Official guidance includes recommendations for maintaining adequate fluid intake to help prevent dehydration, unless otherwise advised by a healthcare provider.


Q: What is the typical timeframe for reviewing the effectiveness of Berlipril H?

Official monitoring guidelines suggest that key checks for effectiveness and safety, such as monitoring blood pressure and running blood tests (for electrolytes and kidney function), should generally take place within 4 to 6 weeks of starting the therapy. Regular monitoring is then advised thereafter.


Q: Can Berlipril H be split or crushed?

Regulatory product monographs generally do not advise or provide instructions for the splitting or crushing of the fixed-dose combination tablet. It is important to follow the tablet's stated administrative route as described in the official product information.


Q: Is Berlipril H considered a first-line treatment for high blood pressure?

Official guidelines state that the combination product is generally not recommended for initial therapy in patients with high blood pressure. While its individual components (ACE inhibitors and thiazide diuretics) are considered preferred options, the combination product is usually reserved for maintenance therapy after individual doses have been established.


Q: How is the long-term safety of Berlipril H described in regulatory documents?

Official documentation describes the product as intended for long-term therapy. The long-term safety profile requires regular monitoring of renal function (kidneys) and electrolyte levels. It is noted that the diuretic component is associated with an increased risk of non-melanoma skin cancer with prolonged use.


Q: What are the common misunderstandings about the 'H' part of the name?

The 'H' in Berlipril H stands for Hydrochlorothiazide, which is the diuretic component, often called a 'water pill.' Official product information emphasizes that this component is associated with warnings, including the need for sun precautions and careful monitoring of electrolyte balance.


Q: Can Berlipril H cause muscle cramps or spasms?

Yes, official product information lists muscle cramps and muscle weakness as possible side effects. These effects are often associated with the diuretic component, which can lead to shifts or imbalances in electrolytes (salts) in the body.


Q: Does Berlipril H require regular blood tests?

Yes, regulatory monitoring guidance recommends regular blood tests for patients taking this medication. These tests are needed to monitor renal function (kidney health) and ensure electrolyte levels (such as potassium) remain within a safe range.


Q: Why is Berlipril H not recommended during the second and third trimesters of pregnancy?

Official warnings state that using the medication during the second and third trimesters is contraindicated because it can cause serious injury or even death to the developing fetus. The medication is known to harm the baby's developing kidneys and lungs, often by reducing the fluid levels around the fetus.


Q: Does Berlipril H have any known effect on blood sugar levels?

Yes, official information indicates that the medication may affect blood sugar levels. For individuals with diabetes, this effect may necessitate more frequent monitoring of blood glucose and possible discussion with a healthcare provider regarding adjustment to existing diabetes medications.

Advertisements

How should Berlipril H be stored and disposed of?

Storage Requirements

Berlipril H must be stored at controlled room temperature, typically between 20^circC and 25^circC (68^circF and 77^circF). To maintain stability, the medication must be kept in its original, tightly closed container and protected from both moisture and direct light.

Regulatory instructions prohibit storage in extreme environments: Do not freeze the tablets and keep them away from excessive heat. It is a mandatory requirement to keep this medicine out of the reach of children to prevent accidental ingestion.

Disposal Instructions

Do not discard outdated or unused Berlipril H in household trash or by flushing it down a toilet or sink unless specific instructions require it. For proper disposal, consult a pharmacist or healthcare professional about local drug take-back programs or specific pharmaceutical waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Berlipril H found in:

A-Z Index: